Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label extension study of lunsekimig in adults with asthma previously enrolled in DRI16762 or ACT18301
CTR20243808Phase 2Active
- Sponsor
- Sanofi
- Start
- May 2025
- Modality
- Nanobodies (VHH) → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of lunsekimig in asthma, sponsored by Sanofi. Started May 2025; status: active.
02
Drugs
lunsekimig
03
Conditions
asthma
Beyond the preview
Go deeper on CTR20243808.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20243808.